SCHEMBL1166945

SCHEMBL1166945

COC(=O)c1ccc(Cn2cc(N)cn2)o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 2/20 0.56
KMT2A Q03164 4/20 0.53
MEN1 O00255 3/20 0.53
HPGD P15428 2/20 0.53
TP53 P04637 1/20 0.53
KDM4E B2RXH2 3/20 0.53
POLB P06746 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 4/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
LMNA P02545 5/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
TDP1 Q9NUW8 2/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 2/20 0.46
MAPK1 P28482 2/20 0.46
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2818616 0.85 LMNA (0.48) ALDH1A1KMT2AMEN1HPGDTP53
SCHEMBL14699394 0.85 LMNA (0.53) ALDH1A1NPSR1KMT2AMEN1HPGD
SCHEMBL1166700 0.81 LMNA (0.71) ALDH1A1KMT2AMEN1HPGDKDM4E
SCHEMBL15189768 0.75 LMNA (0.43) ALDH1A1KMT2AMEN1HPGDTP53
SCHEMBL1167800 0.72 LMNA (0.41) ALDH1A1KMT2AMEN1HPGDTP53
SCHEMBL4444107 0.71 HTT (0.73) ALDH1A1NPSR1KMT2AMEN1HPGD
SCHEMBL12018996 0.70 HTT (1.00) ALDH1A1NPSR1KMT2AMEN1HPGD
SCHEMBL23188937 0.70 LMNA (0.54) ALDH1A1KMT2AMEN1HPGDTP53
SCHEMBL6582577 0.70 ALDH1A1 (0.88) ALDH1A1NPSR1KMT2AKDM4EHTT
Hydrochloric Acid SCHEMBL4444103 0.70 HTT (0.71) ALDH1A1NPSR1KMT2AMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242743-B1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2013-08-21 EP disclosed
CN-101903353-B Aminopyrazole derivatives ACTELION PHARMACEUTICALS LTD 2013-04-10 CN disclosed
US-8288419-B2 Aminopyrazole derivatives ACTELION PHARMACEUTICALS, LTD (CH) 2012-10-16 US disclosed
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES ACTELION (CH) 2011-02-10 US disclosed
CN-101903353-A Aminopyrazole derivatives ACTELION PHARMACEUTICALS LTD 2010-12-01 CN disclosed
EP-2242743-A1 AMINOPYRAZOLE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2010-10-27 EP disclosed
WO-2009077954-A1 AMINOPYRAZOLE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034516-A1 AMINOPYRAZOLE DERIVATIVES CYP3A43, CYP1A2, CYP3A5 ALDH1A1 96/4885NPSR1 578/4885KMT2A 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.